BridgeBio Q3 revenue jumps to $120.7 mln

BridgeBio Pharma

29/10/2025 20:22

Overview

BridgeBio Q3 revenue rises to $120.7 mln, driven by Attruby's commercial launch

Company ends Q3 with $645.9 mln in cash and marketable securities

BridgeBio plans NDA filings for BBP-418 and encaleret in 1H 2026

Outlook

Topline results for PROPEL 3 study of infigratinib expected in early 2026

Result Drivers

ATTRUBY LAUNCH - Strong commercial launch of Attruby contributed $108.1 mln to Q3 revenue, driven by increasing prescriptions and physician adoptionimprovements in serum and urine calcium levels

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.95
Q3 Net Income
-$184.94 mln
Q3 Operating Income
-$145.2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for BridgeBio Pharma Inc is $71.00, about 9.2% above its October 28 closing price of $64.50

Press Release: ID:nGNX3x36tB

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)